Biochemical and pharmacologic comparison of thrombolytic agents

Pharmacotherapy

Volumn 16, Issue 5 II, 1996, Pages

  Stringer, Kathleen A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANISTREPLASE; FIBRINOLYTIC AGENT; RETEPLASE; SARUPLASE; STAPHYLOKINASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ARTERY DIAMETER; BLOOD CLOT LYSIS; CONFERENCE PAPER; DRUG ELIMINATION; DRUG HALF LIFE; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; HUMAN; KRINGLE DOMAIN; SURVIVAL RATE;

AMINO ACID SEQUENCE; ANISTREPLASE; FIBRINOLYTIC AGENTS; HUMANS; MOLECULAR SEQUENCE DATA; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0029833151     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
2. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
3. Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol 1992;17:1-10.
4. Verstraete M, Lijnen H, Collen D. Thrombolytic agents in development. Drugs 1995;50:29-42.
5. Jackson KW, Tang J. Complete amino acid sequence of streptokinase and its homology with serine proteases. Biochemistry 1982;21:6620-5.
6. Rakoczi I, Wiman B, Collen D. On the biological significance of the specific interaction between fibrin, plasminogen, and antiplasmin. Biochim Biophys Acta 1978;540:295-300.
7. Marinac JS, North DS, Stringer KA. Anistreplase: a novel thrombolytic agent for acute myocardial infarction. Ann Pharmacother 1990;24:607-15.
8. Gillis JC, Wagstaff AJ, Goa KL. Alteplase: a reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Drugs 1995;50:102-36.
9. Loscalzo J, Braunwald E. Tissue plasminogen activator. N Engl J Med 1988;319:925-31.
10. de Munk GAW, Rijken DC. Fibrinolytic properties of single-chain urokinase type plasminogen activator (pro-urokinase). Fibrinolysis 1990;4:1-9.
11. Lijnen HR, Collen D. Fibrinolytic agents: mechanisms of activity and pharmacology. Thromb Haemost 1995;74:387-90.
12. PRIMI Trial Study Group. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989;i:863-8.
13. Tebbe U, Windeler J, Boesl I, et al. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). J Am Coll Cardiol 1995;26:365-73.
14. Van de Werf F, Vanhaecke J, de Geest H, Verstraete M, Collen D. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986;74:1066-70.
15. Diefenbach C, Erbel R, Pop T, et al. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction. Am J Cardiol 1988;61:966-70.
16. Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood 1994;84:680-6.
17. Vanderschueren S, Barrios L, Kerdsinchai P, et al. A randomized trial of recombinant Staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995;92:2044-9.
18. McClintock DK, Bell PH. The mechanism of activation of human plasminogen by streptokinase. Biochem Biophys Res Commun 1971;43:694-702.
19. Camiolo SM, Markus G, Evers JL, Hobika GH. Augmentation of streptokinase activator activity by fibrinogen or fibrin. Thromb Res 1980;17:697-706.
20. Goa KL, Henwood JM, Stolz JF, et al. Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction. Drugs 1990;39:693-719.
21. Levine MN, Goldhaber SZ, Gore JM, Hirsh J, Califf RM. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1995;108:291S-301.
22. Tanswell P, Tebbe U, Neuhaus K-L, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992;19:1071-5.
23. Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase, and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992;19:433-40.
24. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995;346:329-36.
25. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared to alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-32.
26. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (rPA) and front-loaded, "accelerated" alteplase (t-PA) in patients with acute myocardial infarction. Circulation In press.
27. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986;67:1215-23.
28. Husain SS. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. Biochemistry 1991;30: 5797-805.
29. Lijnen HR, Van Hoef B, De Cock F, Collen D. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. Blood 1989;73:1864-72.
30. De Boer A, Kluft C, Gerloff J, et al. Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its fibrinolytic and haemostatic parameters in healthy male subjects. Thromb Haemost 1993;70:320-5.
31. Koster RW, Cohen AF, Hopkins GR, Beier H, Gunzler WA, van der Wouw PA. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost 1994;5:40-4.
32. Lijnen HR, Stassen JM, Vanlinthout I, et al. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemost 1991;66:468-73.
33. Collen D, Stassen JM, Silence K, et al. Thrombolytic properties of natural (STAN) and recombinant (STAR) staphylokinase [abstr]. Fibrinolysis 1992;6(suppl 2):52.
34. Clemmensen I, Andersen RB. The fibrinolytic system and its relation to inflammatory diseases. Semin Arthritis Rheum 1982;11:390-8.
35. Stringer KA. Beyond thrombolysis: other effects of thrombolytic drugs. Ann Pharmacother 1994;28:752-6.
36. Stringer KA, Lindenfeld J, Repine AJ, et al. Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro. Inflammation In press.